Norfolk and Norwich University Hospitals have been using two Mostcare Up devices since 2019
News
IIH headaches could be treated with exenatide
The type 2 diabetes therapy is being tested on patients in a phase 2 clinical trial
ICON and LEO Pharma join forces on clinical trial mission
Collaboration will concentrate on launching and running studies within medical dermatology
AstraZeneca’s IMFINZI improves lung cancer survival
Positive results emerge from AEGEAN phase 3 trial for patients with resectable non-small cell lung cancer
FlyPharma Europe, Vienna – 2023 conference officially launched
FlyPharma Europe chose Vienna for its latest conference due to the growing presence of Austrian biotechnology and pharmaceutical manufacturing
Cancer Research UK reach agreement with UCB
The partnership will concentrate on the development of two investigational antibodies
New laboratory space for MSD at The Francis Crick Institute
Move represents the latest phase of preparation for the opening of MSD’s new UK Discovery Centre
Novo Nordisk weight-loss drug available across NHS
NICE has recommended the use of semaglutide alongside a reduced-calorie diet and exercise
Affibody and Chiesi Group partner to develop treatments
Collaboration will focus on innovative therapies for patients with a range of respiratory diseases
SkinBioTherapeutics’ AxisBiotix-Ps gains approval
Company’s skin health product poised for vital European market launch following success in the UK
Noema Pharma raises crucial financing for treatments
Company has raised $112m in order to develop therapies for central nervous system disorders
Protalix and Chiesi gain positive opinion for pegunigalsidase alfa
The therapy becomes the first pegylated enzyme for the treatment of adult patients with Fabry disease
Moderna opts for Oxfordshire in quest for innovation
Vaccines developed at the facility will cover a wide range of respiratory diseases
Sequana Medical announces positive results for DSR 2.0 candidate
Extensive phase 1 clinical trial evaluates safety of treatment among peritoneal patients
Amniotics’ PulmoStem receives positive safety data
Treatment is a lung-specific stem cell therapy designed for hospitalised patients with respiratory infections
